Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 18/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23791487 | 1.00 | OGA (0.38) | OGAOPRK1PDE2AHTR1AHTR1D | |
| SCHEMBL23791486 | 1.00 | OGA (0.38) | OGAOPRK1PDE2AHTR1AHTR1D | |
| SCHEMBL21605963 | 0.94 | OGA (0.40) | OGAOPRK1PDE2A | |
| SCHEMBL21605958 | 0.94 | OGA (0.40) | OGAOPRK1PDE2A | |
| SCHEMBL21605962 | 0.94 | OGA (0.40) | OGAOPRK1PDE2A | |
| SCHEMBL20281979 | 0.85 | OGA (0.52) | OGA | |
| SCHEMBL21603364 | 0.85 | GRM5 (0.35) | OGAOPRK1 | |
| SCHEMBL21603309 | 0.85 | GRM5 (0.35) | OGAOPRK1 | |
| SCHEMBL21603370 | 0.85 | GRM5 (0.35) | OGAOPRK1 | |
| SCHEMBL23871336 | 0.83 | OGA (0.39) | OGAOPRK1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243527-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | OGA 1/4885OPRK1 1977/4885PDE2A 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.